Is the absence of JAK2V617F mutation a risk factor for bleeding in essential thrombocythemia? An analysis of 106 patients

Blood Transfusion

Volumn 8, Issue 1, 2010, Pages 21-27

  Patriarca, Andrea ^a   Pompetti, Franca ^a   Malizia, Raniero ^a   Iuliani, Ornella ^a   Di Marzio, Ilaria ^a   Spadano, Antonio ^a   Dragani, Alfredo ^a  

^a SPIRITO SANTO HOSPITAL   (Italy)

Author keywords

Bleeding; Essential thrombocythaemia; JAK2V617F; Myeloproliferative disorders; Thrombosis

Indexed keywords

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CELL COUNT; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; GENE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HEMATOCRIT; HUMAN; JANUS KINASE 2 V617F GENE; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRV1 GENE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UNIVARIATE ANALYSIS; WILD TYPE; AMINO ACID SUBSTITUTION; BLOOD; GENETICS; LEUKOCYTE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; THROMBOCYTHEMIA;

ALLOANTIGEN; CD177 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MEMBRANE PROTEIN;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; FEMALE; HEMORRHAGE; HUMANS; ISOANTIGENS; JANUS KINASE 2; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MUTATION, MISSENSE; RECEPTORS, CELL SURFACE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 74549226161     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2009.0004-09     Document Type: Article

References (20)

1. V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis. Mayo Clin Proc 2005; 80: 947-58.
2. V617F mutation status: a prospective study. Lancet 2005: 366; 1945-53.
3. V617F mutation status. Haematologica 2007; 92: 135-6.
4. V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients. Blood 2005; 15: 2862-4.
5. Passamonti F, Pietra D, Malabarba L, et al. Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. Br J Haematol 2004; 126: 650-6.
6. V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41.
7. V617F mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208-13.
8. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004; 89: 215-32.
9. Schafer A. Molecular basis of diagnosis and treatment of polycythemia vera and essential thrombocythemia. Blood 2006; 107: 4214-22.
10. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
11. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-61.
12. Germer S, Holland MJ, Higuchi R. High-throughput SNP allele-frequency determination in pooled DNA samples by kinetic PCR. Genome Res 2000; 10: 258-66.
13. V617F in blood. Hemat Oncol 2006; 24: 227-33.
14. Klippel S, Strunck E, Temerinac S, et al. Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis. Blood 2003; 102: 3569-74.
15. V617F polycythemia vera. Cancer 2006; 106: 631-5.
16. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91: 169-75.
17. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and JAK2 mutation status. Blood 2006; 109: 2310-3.
18. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 3135-7.
19. V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2005; 132: 244-5.
20. Radaelli F, Colombi M, Calori R, et al. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia. Hematol Oncol 2007; 25: 115.